Company news
Hemostemix Inc (TSXV:HEM) news
Hemostemix Inc news releases on 6ix. Latest, Oct 11, 2024: Hemostemix's Private Placement
Press releases — page 3
Hemostemix's Private Placement
October 11, 2024
Canadian Investment Regulatory Organization Trade Resumption - HEM
August 2, 2024
Canadian Investment Regulatory Organization Trading Halt - HEM
August 1, 2024
Hemostemix Closes its Funded Manufacturing Services Agreement with CytoImmune, Restarting Production of ACP-01
July 31, 2024
Hemostemix Announces Trademark Granted by Switzerland and Interest Payment
June 11, 2024
Hemostemix Announces Strategic Manufacturing Partnership with CytoImmune Therapeutics and $1,800,000 in Financing Commitments
June 3, 2024
Hemostemix Announces Engagement of Oak Hill Asset Management Inc.
March 7, 2024
Hemostemix Announces Updated Phase II Randomized Clinical Trial Results Published by the Journal of Biomedical Research and Environmental Sciences
February 6, 2024
Hemostemix Clarifies its October 3, 2023 News Release
December 29, 2023
Hemostemix's 4th Heart Study Published in Stem Cell Research & Therapy Confirms Breakthrough Treatment for Heart Disease
October 30, 2023
Hemostemix Announces Amendment of its $2.5 Million 5 Year Convertible Debenture Issued on June 11, 2021, Resulting in an Expected Interest Saving of Approximately $570,000
October 23, 2023
Hemostemix Closed $320,125 Private Placement
October 3, 2023
Hemostemix Announces New Publication: How NCP-01 Supports Brain Computer Interfaces
September 12, 2023
Hemostemix Announces the Incorporation of Hemostemix Quebec Inc. and $6 Million in Grant Applications
August 29, 2023
Hemostemix Announces Arbitration Award of CAD $315,684 Plus Private Placement
August 14, 2023
Hemostemix Submits Its Retrospective Heart Study to Leading Stem Cell Journal and Has Prepared Its CLI Phase II Clinical Trial Manuscript for Peer Review
August 8, 2023
Hemostemix Closes $403,539 of the Unit Private Placement
June 28, 2023
Hemostemix's Private Placement Use of Proceeds
June 21, 2023
Hemostemix Announces Unit Private Placement
May 31, 2023
TSX Venture Exchange Stock Maintenance Bulletins
May 3, 2023
IIROC Trading Resumption - HEM
May 2, 2023
Hemostemix (PreCerv Inc.) Retains Chris McNorgan PhD to License NCP-01 to Neural Electrode Brain Implant Company
May 2, 2023
IIROC Trading Halt - HEM
May 2, 2023
Hemostemix' Second Round Interviews with Executive Vice President Business Development Candidates
April 3, 2023
Hemostemix Engages Montreal's RobboDesign to SEO Its Website to Engage with 236 Million Peripheral Arterial Disease and Critical Limb Ischemia Patients Globally
March 29, 2023
Hemostemix Closes $762,400 of The Unit Private Placement
March 21, 2023
Hemostemix Unit Offering Repriced
March 8, 2023
Hemostemix Offers up to 500 6% Convertible Debentures, Convertible into an ACP-01 Therapeutic Production Slot that is Subject to Compassionate Exemption from Regulatory Approval
March 7, 2023
The Force Family Office Engaged by Hemostemix
January 31, 2023
Hemostemix' "Your Fountain of Youth" Trademark Granted by Switzerland
January 30, 2023
Hemostemix' "Your Fountain of Youth" Trademark Granted by Japan Patent Office
January 26, 2023
Hemostemix Wins Arbitration Decision
January 24, 2023
Hemostemix Hiring 4 New Biotechnologists in Montreal and Appling for Grants to Fund Up To 75% of 5-Year Costs
January 23, 2023
Hemostemix Announces Letter of Commitment, Non-Dilutive Funding Structure and $250,000 of Funding by the McGill University Health Centre Foundation
January 19, 2023
Hemostemix Issued 'Your Fountain of Youth' Trademark by Cyprus
December 8, 2022
Hemostemix Thanks Neim Malo, Beefstro's Founder, for His ACP-01 Testimonial Interview
November 30, 2022
Hemostemix Thanks Six-Time Grammy Award Winner, Howie Lindeman, for his ACP-01 Testimonial Interview
November 17, 2022
Hemostemix Announces Advancements in Its Automation of Production
November 15, 2022
Hemostemix Announces Dr. Giannetti and Dr. Cecere as Co-Lead Medical Consultants, Cardiovascular Clinical Trials
October 26, 2022
Hemostemix Announces Presentation to the Emerging Growth Conference
October 25, 2022
Hemostemix Announces NCP-01 Study to Address a $10 Billion Pain Market
October 19, 2022
Hemostemix Announces Exploring Clinical Trial Financing Alternatives
October 4, 2022
Hemostemix Announces the Appointment of Dr. Ernst von Schwarz, MD, PhD, FESC, FACC, FSCAI to Its Scientific Advisory Board
September 27, 2022
Hemostemix Announces the Appointment of Dr. Terry Hébert, PhD, to Its Scientific Advisory Board
September 20, 2022
Hemostemix Announces the Appointment of Dr. Nadia Giannetti, MD, to its Scientific Advisory Board
September 16, 2022
Hemostemix Announces the Appointment of Dr. Johannes Grillari to its Scientific Advisory Board
September 15, 2022
Hemostemix Announces the Appointment of Dr. Renzo Cecere, MD, FRCSC to Its Scientific Advisory Board
September 14, 2022
Hemostemix Announces Its Presentation to the Emerging Growth Conference
September 14, 2022
Hemostemix Announces the Appointment of Thomas Abraham, CA as President, PreCerv Inc.
September 13, 2022
Hemostemix Announces A Clarification
August 31, 2022